NCT Number stringlengths 11 11 | Study Title stringlengths 18 300 | Study URL stringlengths 44 44 | Study Status stringclasses 13
values | Conditions stringlengths 3 11.1k ⌀ | Interventions stringlengths 5 1.2k ⌀ | Sponsor stringlengths 3 121 | Collaborators stringlengths 2 3.21k ⌀ | Study Type stringclasses 3
values |
|---|---|---|---|---|---|---|---|---|
NCT01252277 | Breast Cancer Risk Biomarkers in Premenopausal Women | https://clinicaltrials.gov/study/NCT01252277 | COMPLETED | Breast Cancer | DRUG: Lovaza™ | Carol Fabian, MD | null | INTERVENTIONAL |
NCT00390377 | Use of Hair to Diagnose Breast Cancer | https://clinicaltrials.gov/study/NCT00390377 | UNKNOWN | Breast Cancer | PROCEDURE: Cutting scalp hair | Fermiscan Ltd | null | INTERVENTIONAL |
NCT01088477 | Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer | https://clinicaltrials.gov/study/NCT01088477 | COMPLETED | Breast Cancer | OTHER: Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol | University Medical Center Groningen | Dutch Cancer Society | OBSERVATIONAL |
NCT00793377 | Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer | https://clinicaltrials.gov/study/NCT00793377 | COMPLETED | Primary Breast Cancer | DRUG: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|DRUG: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid | German Breast Group | German Adjuvant Breast Cancer Group | INTERVENTIONAL |
NCT04461977 | Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer | https://clinicaltrials.gov/study/NCT04461977 | UNKNOWN | Peripheral Neuropathy Due to Chemotherapy | OTHER: True acupuncture|OTHER: Sham acupuncture | Instituto Brasileiro de Controle do Cancer | null | INTERVENTIONAL |
NCT06188494 | UNFOLD Study Egypt | https://clinicaltrials.gov/study/NCT06188494 | NOT_YET_RECRUITING | Breast Cancer | null | AstraZeneca | null | OBSERVATIONAL |
NCT05422794 | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | https://clinicaltrials.gov/study/NCT05422794 | RECRUITING | Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Triple-Negative Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma | DRUG: BET Bromodomain Inhibitor ZEN-3694|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|BIOLOGICAL: Pembrolizumab | National Cancer Institute (NCI) | null | INTERVENTIONAL |
NCT05122494 | A Phase Ⅲ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT05122494 | RECRUITING | Breast Cancer | DRUG: Hemay022+AI|DRUG: Lapatinib+Capecitabine | Tianjin Hemay Oncology Pharmaceutical Co., Ltd | null | INTERVENTIONAL |
NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | https://clinicaltrials.gov/study/NCT05000294 | SUSPENDED | Bile Duct Cancer|Gall Bladder Cancer|Breast Cancer|Neuroendocrine Tumors|Ovarian Cancer|Pancreatic Adenocarcinoma|Soft Tissue Sarcoma|Vulvar Cancer|Prostate Cancer | DRUG: Atezolizumab|DRUG: Tivozanib | University of Florida | Genentech, Inc.|Aveo Oncology Pharmaceuticals | INTERVENTIONAL |
NCT00790894 | Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) | https://clinicaltrials.gov/study/NCT00790894 | TERMINATED | Metastatic Breast Cancer | DRUG: ixabepilone|DRUG: ixabepilone | Hellenic Cooperative Oncology Group | null | INTERVENTIONAL |
NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer | https://clinicaltrials.gov/study/NCT05134194 | UNKNOWN | Triple Negative Breast Cancer | DRUG: Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|DRUG: Capecitabine/eribulin/gemcitabine/vinorelbine | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | null | INTERVENTIONAL |
NCT01222377 | Endoscopic Breast Surgery in Treating Patients With Breast Cancer | https://clinicaltrials.gov/study/NCT01222377 | TERMINATED | Male Breast Cancer|Recurrent Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | PROCEDURE: endoscopic surgery|PROCEDURE: quality-of-life assessment | University of Southern California | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT02569294 | Feasibility and Impact of Group Interventions on Breast Cancer Patients Well-being | https://clinicaltrials.gov/study/NCT02569294 | COMPLETED | Breast Cancer | BEHAVIORAL: Yoga intervention|BEHAVIORAL: Hypnosis intervention|BEHAVIORAL: CBT intervention | University of Liege | null | INTERVENTIONAL |
NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | https://clinicaltrials.gov/study/NCT04147494 | RECRUITING | Breast Carcinoma|Colon Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Head and Neck Carcinoma|Kidney Carcinoma|Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma|Solid Neoplasm|Uterine Corpus Cancer | PROCEDURE: Computed Tomography|RADIATION: Gallium Ga 68 FAPi-46|RADIATION: Gallium Ga 68-labeled PSMA-11|PROCEDURE: Positron Emission Tomography|RADIATION: 18F-FDG | Jonsson Comprehensive Cancer Center | Society of Nuclear Medecine and Molecular Imaging | INTERVENTIONAL |
NCT03328494 | Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies | https://clinicaltrials.gov/study/NCT03328494 | COMPLETED | Advanced Nonhaematologic Malignancies | DRUG: BOS172722|DRUG: Paclitaxel | Boston Pharmaceuticals | null | INTERVENTIONAL |
NCT02991677 | Exercise Effect on Chemotherapy-Induced Neuropathic Pain | https://clinicaltrials.gov/study/NCT02991677 | UNKNOWN | Cancer, Breast|Cancer, Colorectal|Cancer, Lung|Cancer, Ovarian | BEHAVIORAL: aerobic exercise intervention|OTHER: control group|BEHAVIORAL: resistive training | Baltimore VA Medical Center | null | INTERVENTIONAL |
NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | https://clinicaltrials.gov/study/NCT01275677 | ACTIVE_NOT_RECRUITING | HER2/Neu Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Trastuzumab | National Cancer Institute (NCI) | NRG Oncology | INTERVENTIONAL |
NCT05968677 | Effect of an Amino Acids and Flavonoids Containing FSMP on Chemotherapy Toxicity, Nutritional Status and Quality of Life in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT05968677 | RECRUITING | Breast Cancer | DIETARY_SUPPLEMENT: FSMP|OTHER: Nutritional counseling | Flavolife Srl | null | INTERVENTIONAL |
NCT05291494 | A Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT05291494 | COMPLETED | Breast Cancer Female | BEHAVIORAL: follow the WeChat public platform to watch the education videos|BEHAVIORAL: regular preoperative visits and education by ward nurses. | West China Hospital | null | INTERVENTIONAL |
NCT04532177 | Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery | https://clinicaltrials.gov/study/NCT04532177 | ACTIVE_NOT_RECRUITING | Breast Cancer | RADIATION: Stereotactic Body Radiation Therapy (SBRT) | Stony Brook University | null | INTERVENTIONAL |
NCT03106077 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | https://clinicaltrials.gov/study/NCT03106077 | COMPLETED | Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer... | BIOLOGICAL: Mirvetuximab Soravtansine | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT03888677 | Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer | https://clinicaltrials.gov/study/NCT03888677 | COMPLETED | Breast Cancer | DRUG: 5-FU, epirubicin and cyclophosphamide | Henrik Lindman | Scandinavian Breast Group|Danish Breast Cancer Cooperative Group|Swedish Cancer Society|Swedish Cancer Foundation|Pharmacia Pharmaceutical Company|Swedish Breast Cancer Group | INTERVENTIONAL |
NCT05288777 | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer | https://clinicaltrials.gov/study/NCT05288777 | RECRUITING | Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III | DRUG: T-DM1|DRUG: Capecitabine|RADIATION: External Beam Radiation Therapy 0|RADIATION: External Beam Radiation Therapy 1 | University of Virginia | null | INTERVENTIONAL |
NCT02521077 | Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer | https://clinicaltrials.gov/study/NCT02521077 | WITHDRAWN | Fatigue | DRUG: Ascorbic Acid|OTHER: Normal Saline | Midwestern Regional Medical Center | null | INTERVENTIONAL |
NCT03789877 | A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity | https://clinicaltrials.gov/study/NCT03789877 | COMPLETED | Cancer Survivor|Invasive Breast Carcinoma | OTHER: Physical Activity|OTHER: Questionnaire Administration|PROCEDURE: Repetitive Transcranial Magnetic Stimulation|PROCEDURE: Sham Intervention | Roswell Park Cancer Institute | null | INTERVENTIONAL |
NCT01980277 | Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT01980277 | TERMINATED | Breast Cancer | DRUG: LY2780301 + paclitaxel | Institut Paoli-Calmettes | null | INTERVENTIONAL |
NCT05587777 | Monitoring of Chronic Conditions in Breast Cancer | https://clinicaltrials.gov/study/NCT05587777 | RECRUITING | Breast Cancer|Chronic Fatigue Syndrome | null | Helse Stavanger HF | null | OBSERVATIONAL |
NCT04767594 | First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting. | https://clinicaltrials.gov/study/NCT04767594 | RECRUITING | Breast Neoplasms | DRUG: Palbociclib + endocrine therapy | Pfizer | null | OBSERVATIONAL |
NCT00148694 | Preoperative Cisplatin in Early Stage Breast Cancer | https://clinicaltrials.gov/study/NCT00148694 | COMPLETED | Breast Cancer | DRUG: Cisplatin | Dana-Farber Cancer Institute | Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Brigham and Women's Hospital|Breast Cancer Research Foundation | INTERVENTIONAL |
NCT03043794 | Study of Stereotactic Radiotherapy for Breast Cancer | https://clinicaltrials.gov/study/NCT03043794 | RECRUITING | Breast Cancer | RADIATION: Stereotactic Body Radiation SBRT | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | null | INTERVENTIONAL |
NCT03321929 | Intraoperative Detection of Residual Cancer in Breast Cancer | https://clinicaltrials.gov/study/NCT03321929 | COMPLETED | Breast Cancer | COMBINATION_PRODUCT: LUM Imaging System | Lumicell, Inc. | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT04953377 | PFMT Educational Intervention for Patients With Advancer Breast Cancer | https://clinicaltrials.gov/study/NCT04953377 | RECRUITING | Advanced Breast Cancer | BEHAVIORAL: PFMT educational intervention | Onkologikoa | null | INTERVENTIONAL |
NCT01594177 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy | https://clinicaltrials.gov/study/NCT01594177 | COMPLETED | Unilateral HER2 Positive Breast Cancer | DRUG: Afatinib|DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide | German Breast Group | Boehringer Ingelheim | INTERVENTIONAL |
NCT01625429 | Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer | https://clinicaltrials.gov/study/NCT01625429 | UNKNOWN | Breast Cancer | DRUG: nab-paclitaxel | Shanghai Cancer Hospital, China | null | INTERVENTIONAL |
NCT05928429 | Effects of Cryotherapy on Taxane-Induced Neuropathy in Patients With Breast Cancer | https://clinicaltrials.gov/study/NCT05928429 | RECRUITING | CIPN - Chemotherapy-Induced Peripheral Neuropathy|Breast Cancer | DEVICE: Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA | Maria Lendorf | Danish Cancer Society|Aarhus University Hospital|Nordsjællands Hospital, Denmark|Hospital of Southern Jutland | INTERVENTIONAL |
NCT00333229 | A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss | https://clinicaltrials.gov/study/NCT00333229 | TERMINATED | Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women | DRUG: Zoledronic Acid|DRUG: Placebo | Novartis Pharmaceuticals | null | INTERVENTIONAL |
NCT04755829 | Breath Test to Predict Breast Cancer and Outcome of Mammography | https://clinicaltrials.gov/study/NCT04755829 | UNKNOWN | Breast Cancer|Abnormal Mammogram, Unspecified | DEVICE: BreathX test for breath VOCs | Menssana Research, Inc. | Mount Vernon Cancer Centre|Zuyderland Medical Centre|University of Erlangen-Nürnberg | OBSERVATIONAL |
NCT01978977 | Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT01978977 | COMPLETED | Metastatic Breast Cancer | null | Hellenic Oncology Research Group | null | OBSERVATIONAL |
NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | https://clinicaltrials.gov/study/NCT05275777 | RECRUITING | HER2-negative Breast Cancer|Advanced Solid Tumor | DRUG: ADG106|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel | National University Hospital, Singapore | Adagene Inc | INTERVENTIONAL |
NCT05257577 | Factors Influencing Breast Cancer Resection Volumes And Their Impact on Treatment Outcome (FIBRATIO) | https://clinicaltrials.gov/study/NCT05257577 | ENROLLING_BY_INVITATION | Breast Cancer|Quality of Life|Patient Satisfaction|Resection Margin|Surgical Margin|Multidisciplinary Communication | PROCEDURE: Breast conserving surgery | Tampere University Hospital | Jyväskylä Central Hospital|Turku University Hospital|Kuopio University Hospital|North Karelia Central Hospital | OBSERVATIONAL |
NCT00849329 | A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer | https://clinicaltrials.gov/study/NCT00849329 | COMPLETED | Neoplasms, Breast | DRUG: lapatinib|DRUG: lapatinib plus esomeprazole | GlaxoSmithKline | null | INTERVENTIONAL |
NCT04881929 | Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | https://clinicaltrials.gov/study/NCT04881929 | RECRUITING | Breast Cancer | DRUG: KN026 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | null | INTERVENTIONAL |
NCT04341129 | Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine) | https://clinicaltrials.gov/study/NCT04341129 | COMPLETED | Breast Neoplasms|Breast Diseases|Breast Fibroadenoma|Breast Cancer | DRUG: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine) | University of Chicago | Guerbet | INTERVENTIONAL |
NCT00662129 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT00662129 | COMPLETED | Breast Cancer | BIOLOGICAL: bevacizumab|DRUG: gemcitabine hydrochloride|DRUG: paclitaxel albumin-stabilized nanoparticle formulation | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT04012229 | IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | https://clinicaltrials.gov/study/NCT04012229 | COMPLETED | Breast Cancer|BRCA1 Mutation|BRCA2 Mutation | GENETIC: BRCA mutation | Centre Hospitalier Universitaire de Besancon | null | OBSERVATIONAL |
NCT02041429 | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | https://clinicaltrials.gov/study/NCT02041429 | COMPLETED | Recurrent Breast Cancer|Metastatic Breast Cancer | DRUG: Ruxolitinib|DRUG: Paclitaxel | Dana-Farber Cancer Institute | Incyte Corporation | INTERVENTIONAL |
NCT00385177 | Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors | https://clinicaltrials.gov/study/NCT00385177 | COMPLETED | Breast Neoplasms|Colorectal Neoplasms|Pancreatic Neoplasms|Pelvic Neoplasms|Lung Neoplasms | DRUG: SN2310 Injectable Emulsion | Achieve Life Sciences | null | INTERVENTIONAL |
NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | https://clinicaltrials.gov/study/NCT05564377 | RECRUITING | Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic HER2-Negative Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Recurrent Endometrial Carcinoma|Recurre... | DRUG: Alpelisib|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|DRUG: Fluorouracil|DRUG: Fulvestrant|DRUG: Ipatasertib|DRUG: Leucovorin|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE:... | National Cancer Institute (NCI) | null | INTERVENTIONAL |
NCT04689529 | Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer | https://clinicaltrials.gov/study/NCT04689529 | ACTIVE_NOT_RECRUITING | Breast Cancer|Surgery|IMAGE|Chemotherapy Effect | DIAGNOSTIC_TEST: Preoperative imaging study | Seoul National University Hospital | null | INTERVENTIONAL |
NCT00003877 | Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT00003877 | COMPLETED | Breast Cancer | BIOLOGICAL: filgrastim|DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: paclitaxel|DRUG: thiotepa|PROCEDURE: in vitro-treated bone marrow transplantation|PROCEDURE: in vitro-treated peripheral blood stem cell transplantation | Roswell Park Cancer Institute | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT01649271 | Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. | https://clinicaltrials.gov/study/NCT01649271 | COMPLETED | Breast Neoplasms|Stomach Neoplasms | DRUG: Herceptin|DRUG: afatinib|DRUG: trastuzumab|DRUG: Herceptin|DRUG: afatinib|DRUG: afatinib | Boehringer Ingelheim | null | INTERVENTIONAL |
NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | https://clinicaltrials.gov/study/NCT01702571 | COMPLETED | Breast Cancer | DRUG: Trastuzumab Emtansine | Hoffmann-La Roche | null | INTERVENTIONAL |
NCT01120171 | Myocet Plus Endoxan for Older Patients With Breast Cancer | https://clinicaltrials.gov/study/NCT01120171 | TERMINATED | Breast Cancer | DRUG: Cyclophosphamide|DRUG: Liposomal-encapsulated doxorubicin | Hellenic Oncology Research Group | null | INTERVENTIONAL |
NCT03939871 | A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer | https://clinicaltrials.gov/study/NCT03939871 | UNKNOWN | Hormone Receptor Positive Advanced Breast Cancer | DRUG: fluvestrant + oral vinorelbine | Chinese Academy of Medical Sciences | null | INTERVENTIONAL |
NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT05894239 | RECRUITING | Metastatic Breast Cancer | DRUG: Inavolisib|DRUG: Phesgo|DRUG: Placebo|DRUG: Taxane-based Chemotherapy|DRUG: Optional Endocrine Therapy of Investigator's Choice | Hoffmann-La Roche | null | INTERVENTIONAL |
NCT00393939 | Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer | https://clinicaltrials.gov/study/NCT00393939 | COMPLETED | Breast Neoplasms | DRUG: Sunitinib malate|DRUG: Taxotere | Pfizer | null | INTERVENTIONAL |
NCT00967239 | Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2 | https://clinicaltrials.gov/study/NCT00967239 | UNKNOWN | Breast Cancer | GENETIC: DNA analysis|GENETIC: polymorphism analysis|OTHER: laboratory biomarker analysis|OTHER: pharmacogenomic studies | NSABP Foundation Inc | National Cancer Institute (NCI) | OBSERVATIONAL |
NCT01367639 | Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers | https://clinicaltrials.gov/study/NCT01367639 | COMPLETED | Hereditary Breast and Ovarian Cancer Syndrome | BEHAVIORAL: Inquiry Based Stress Reduction (IBSR) program | Sheba Medical Center | null | INTERVENTIONAL |
NCT03265379 | Improving Quality of Life for Patients With Breast Cancer Invading the Chest Wall: A Prospective Registry For Patients Undergoing Full Thickness Chest Wall Resection | https://clinicaltrials.gov/study/NCT03265379 | RECRUITING | Breast Cancer | OTHER: FACT-B and Brief Pain Inventory | University Health Network, Toronto | null | OBSERVATIONAL |
NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment | https://clinicaltrials.gov/study/NCT04028479 | RECRUITING | Adenocarcinoma|Adenocystic Carcinoma|Anal Cancer|Appendix Cancer|Brain Tumor|Glioblastoma|Astrocytoma|Bile Duct Cancer|Cholangiocarcinoma|Bladder Cancer|Bone Cancer|Synovial Sarcoma|Chondrosarcoma|Liposarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Sarcoma|Osteosarcoma|CNS Cancer|Brain Stem Neoplasms|Breast Cancer|Cervical... | DIAGNOSTIC_TEST: Biomarker Testing (L)|DRUG: Systemic Treatment (T)|OTHER: Patient Reported Outcomes (P) | Taproot Health | null | OBSERVATIONAL |
NCT00419679 | Use of Hair to Diagnose Breast Cancer | https://clinicaltrials.gov/study/NCT00419679 | UNKNOWN | Breast Neoplasms | PROCEDURE: x-ray diffraction of human hair | Fermiscan Ltd | null | INTERVENTIONAL |
NCT03176979 | Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer | https://clinicaltrials.gov/study/NCT03176979 | COMPLETED | Breast Carcinoma | OTHER: Contrast Agent|PROCEDURE: Digital Tomosynthesis Mammography|PROCEDURE: Dual-Energy Contrast-Enhanced Digital Spectral Mammography | University of Southern California | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT05739591 | Long-term Safety and Efficacy of GBG Study Participants | https://clinicaltrials.gov/study/NCT05739591 | RECRUITING | Breast Cancer | null | German Breast Group | null | OBSERVATIONAL |
NCT02902991 | The Study on the Clinical Utility of Liquid Biopsy in Breast Cancer | https://clinicaltrials.gov/study/NCT02902991 | UNKNOWN | Breast Cancer | null | Peking Union Medical College | null | OBSERVATIONAL |
NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | https://clinicaltrials.gov/study/NCT01254591 | UNKNOWN | Breast Cancer|Colorectal Cancer|Esophageal Cancer|Head and Neck Cancer|Lung Cancer | OTHER: 18F-fluoromisonidazole|OTHER: fluorescence angiography|OTHER: laboratory biomarker analysis|PROCEDURE: infrared thermography|PROCEDURE: magnetic resonance imaging|PROCEDURE: therapeutic conventional surgery|RADIATION: [18F]-ML-10|RADIATION: fludeoxyglucose F 18|RADIATION: rubidium Rb-82 | University College London (UCL) Cancer Institute | null | INTERVENTIONAL |
NCT00046891 | EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer | https://clinicaltrials.gov/study/NCT00046891 | COMPLETED | Breast Cancer|Neurotoxicity | DRUG: Ginkgo Biloba|OTHER: Placebo | Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers | https://clinicaltrials.gov/study/NCT05986071 | NOT_YET_RECRUITING | Breast Cancer | DRUG: M1774|DRUG: Fulvestrant injection | Institut Paoli-Calmettes | Merck Sharp & Dohme LLC|National Cancer Institute, France | INTERVENTIONAL |
NCT02248571 | Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | https://clinicaltrials.gov/study/NCT02248571 | COMPLETED | Breast Cancer Recurrent|HER2/Neu-negative Carcinoma of Breast|Hormone Receptor Positive Malignant Neoplasm of Breast | DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Everolimus|DRUG: Exemestane|OTHER: Patient questionaires | iOMEDICO AG | Arbeitsgemeinschaft fur Internistische Onkologie|Novartis Pharmaceuticals | INTERVENTIONAL |
NCT04496739 | Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE) | https://clinicaltrials.gov/study/NCT04496739 | RECRUITING | Atypical Hyperplasia of the Breast|Lobular Breast Carcinoma In Situ|Pleomorphic Lobular Breast Carcinoma In Situ | BEHAVIORAL: Cancer Educational Materials|OTHER: Decision Aid|OTHER: Decision Aid|OTHER: Interview|OTHER: Questionnaire Administration | SWOG Cancer Research Network | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT03257839 | Delphinus SoftVue Prospective Case Collection - ARM 1 | https://clinicaltrials.gov/study/NCT03257839 | COMPLETED | Breast Neoplasms | DEVICE: Routine Full-Field Digital Mammography|DEVICE: Routine Digital Breast Tomosynthesis|DEVICE: Automated Whole Breast Ultrasound | Delphinus Medical Technologies, Inc. | null | OBSERVATIONAL |
NCT05720039 | Robotic vs. Open NSM for Early Stage Breast Cancer | https://clinicaltrials.gov/study/NCT05720039 | RECRUITING | Breast Cancer Female|Breast Cancer|Breast Cancer, Early-Onset|Breast Disease|Breast | DEVICE: Robotic NSM|PROCEDURE: Open NSM | Intuitive Surgical | null | INTERVENTIONAL |
NCT00074139 | Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer | https://clinicaltrials.gov/study/NCT00074139 | WITHDRAWN | Breast Cancer | DRUG: cyclophosphamide|DRUG: docetaxel|DRUG: doxorubicin hydrochloride | Case Comprehensive Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT04657679 | Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts | https://clinicaltrials.gov/study/NCT04657679 | TERMINATED | Breast Cancer | DRUG: Ribociclib | Georgetown University | Medstar Health Research Institute|Breast Cancer Research Foundation|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) | INTERVENTIONAL |
NCT00496379 | ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases | https://clinicaltrials.gov/study/NCT00496379 | TERMINATED | Breast Cancer|CNS Disease | DRUG: ZK219477 | Nancy Lin, MD | Brigham and Women's Hospital|Bayer|Breast Cancer Research Foundation | INTERVENTIONAL |
NCT05633979 | Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT05633979 | RECRUITING | Breast Cancer | DRUG: Trastuzumab deruxtecan|DRUG: Valemetostat | M.D. Anderson Cancer Center | Daiichi Sankyo | INTERVENTIONAL |
NCT01463891 | Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) | https://clinicaltrials.gov/study/NCT01463891 | COMPLETED | Inoperable or Recurrent Breast Cancer | DRUG: Eribulin Mesylate | Eisai Co., Ltd. | null | OBSERVATIONAL |
NCT00161291 | Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer | https://clinicaltrials.gov/study/NCT00161291 | COMPLETED | Breast Cancer | DRUG: Letrozole in combination with Bevacizumab | University of Alabama at Birmingham | Genentech, Inc. | INTERVENTIONAL |
NCT05365191 | A Study Evaluating Near-infrared Zone II Imaging in Sentinel Lymph Node Mapping in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT05365191 | RECRUITING | Breast Cancer|Sentinel Lymph Node | PROCEDURE: Near infrared fluorescence navigated sentinel lymph node mapping | National Taiwan University Hospital Hsin-Chu Branch | National Yang Ming Chiao Tung University | INTERVENTIONAL |
NCT01846091 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | https://clinicaltrials.gov/study/NCT01846091 | COMPLETED | Estrogen Receptor Negative|Estrogen Receptor Positive|Head and Neck Squamous Cell Carcinoma|HER2/Neu Negative|HER2/Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Head and Neck Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma | OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter | Mayo Clinic | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT03564171 | Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer | https://clinicaltrials.gov/study/NCT03564171 | COMPLETED | Breast Cancer|Rehabilitation|Neoadjuvant Therapy|Feasibility Studies | COMBINATION_PRODUCT: Prehabilitation | Sunnybrook Health Sciences Centre | University Health Network, Toronto | INTERVENTIONAL |
NCT02780271 | Diet and Physical Activity Changes Among Latina Breast Cancer Survivors | https://clinicaltrials.gov/study/NCT02780271 | COMPLETED | Breast Cancer | BEHAVIORAL: In-person education|BEHAVIORAL: E-communication|BEHAVIORAL: Control | Columbia University | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT02620371 | Efficacy of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain | https://clinicaltrials.gov/study/NCT02620371 | COMPLETED | Breast Cancer | PROCEDURE: modified pectoral block | Assiut University | null | INTERVENTIONAL |
NCT00246571 | Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer | https://clinicaltrials.gov/study/NCT00246571 | COMPLETED | Breast Neoplasms | DRUG: SU011248|DRUG: Chemotherapy | Pfizer | null | INTERVENTIONAL |
NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | https://clinicaltrials.gov/study/NCT05891171 | RECRUITING | Advanced Cancer|Advanced Malignancies|Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Gastroesophageal-junction Cancer (GEJ)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Non-Small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Renal Cell Carcinoma (RCC)|Triple Negative Breast Cancer (TNBC) | DRUG: AB598|DRUG: Zimberelimab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin | Arcus Biosciences, Inc. | null | INTERVENTIONAL |
NCT04175639 | mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients | https://clinicaltrials.gov/study/NCT04175639 | RECRUITING | Breast Cancer | BEHAVIORAL: Mobile Health Pain Coping Skills Training (mPCST) | Duke University | null | INTERVENTIONAL |
NCT01313039 | Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer | https://clinicaltrials.gov/study/NCT01313039 | COMPLETED | Breast Cancer | DRUG: AZ6244 | University of Miami | null | INTERVENTIONAL |
NCT00976339 | Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer | https://clinicaltrials.gov/study/NCT00976339 | COMPLETED | Breast Cancer | DRUG: Cholecalciferol | Katherine D. Crew | Prevent Cancer Foundation | INTERVENTIONAL |
NCT05287139 | QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions. | https://clinicaltrials.gov/study/NCT05287139 | ENROLLING_BY_INVITATION | Quality of Life|Breast Neoplasm Female | OTHER: Quality of Life | Beneficência Portuguesa de São Paulo | null | OBSERVATIONAL |
NCT03579979 | Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG | https://clinicaltrials.gov/study/NCT03579979 | COMPLETED | Sentinel Lymph Node|Breast Cancer | DRUG: Methylene Blue|DRUG: Indocyanine Green | Chinese Academy of Sciences | Beijing Digital Precesion Medicine Company|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Friendship Hospital|Tangshan People's Hospital|The Second Hospital of Hebei Medical University | INTERVENTIONAL |
NCT00952679 | Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients | https://clinicaltrials.gov/study/NCT00952679 | UNKNOWN | Breast Cancer | DEVICE: Breast Lesion Localization Needles (interv) | Fudan University | null | INTERVENTIONAL |
NCT02022579 | DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer | https://clinicaltrials.gov/study/NCT02022579 | UNKNOWN | Breast Cancer|BIRADS 3|BIRADS 4|BIRADS 5 | PROCEDURE: DCE-MRI and DWI | American College of Radiology Imaging Network | National Cancer Institute (NCI)|Eastern Cooperative Oncology Group | INTERVENTIONAL |
NCT04166279 | The Recovery of Reaching Movement in Breast Cancer Survivors: Two Different Rehabilitative Protocols in Comparison | https://clinicaltrials.gov/study/NCT04166279 | COMPLETED | Breast Cancer|Breast Cancer Lymphedema|Pain|Pain, Postoperative|Pain, Chronic|Mastectomy; Lymphedema|Breast Surgery | OTHER: Single rehabilitative treatment|OTHER: Group rehabilitative treatment | University of Roma La Sapienza | null | INTERVENTIONAL |
NCT01479179 | Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | https://clinicaltrials.gov/study/NCT01479179 | WITHDRAWN | Breast Cancer | DRUG: AMG 479|DRUG: Trastuzumab | M.D. Anderson Cancer Center | Amgen | INTERVENTIONAL |
NCT05011279 | Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives) | https://clinicaltrials.gov/study/NCT05011279 | COMPLETED | Breast Cancer Survivor|Breast Cancer|Fitness Trackers | OTHER: Move Together app/Garmin Activity Tracker | Dana-Farber Cancer Institute | University of Massachusetts, Boston|University of Rochester|National Cancer Institute (NCI) | INTERVENTIONAL |
NCT04683679 | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | https://clinicaltrials.gov/study/NCT04683679 | RECRUITING | Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer | DRUG: Pembrolizumab|DRUG: Olaparib|RADIATION: Radiation | Memorial Sloan Kettering Cancer Center | null | INTERVENTIONAL |
NCT04206891 | CDH1 Germline Mutations in Lobular Breast Cancer | https://clinicaltrials.gov/study/NCT04206891 | ACTIVE_NOT_RECRUITING | Lobular Breast Carcinoma|CDH1 Gene Inactivation | null | European Institute of Oncology | null | OBSERVATIONAL |
NCT04583891 | Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design | https://clinicaltrials.gov/study/NCT04583891 | ACTIVE_NOT_RECRUITING | Depression, Anxiety|Engagement, Patient | BEHAVIORAL: IntelliCare|BEHAVIORAL: Psychoeducation|BEHAVIORAL: Coaching | University of Virginia | Northwestern University | INTERVENTIONAL |
NCT05731791 | Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation | https://clinicaltrials.gov/study/NCT05731791 | RECRUITING | Breast Cancer | RADIATION: Radiation Therapy to partial breast | Weill Medical College of Cornell University | null | INTERVENTIONAL |
NCT00014391 | Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation | https://clinicaltrials.gov/study/NCT00014391 | COMPLETED | Cancer | BIOLOGICAL: palivizumab|DRUG: ribavirin | Fred Hutchinson Cancer Center | National Cancer Institute (NCI) | INTERVENTIONAL |
NCT05297591 | Identifying Prognostic Variables for Persistent Upper Limb Dysfunctions After Breast Cancer Treatment | https://clinicaltrials.gov/study/NCT05297591 | RECRUITING | Breast Cancer | OTHER: assessment of UL function and prognostic factors | KU Leuven | Universitaire Ziekenhuizen KU Leuven|Vrije Universiteit Brussel | INTERVENTIONAL |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 2